These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1122 related items for PubMed ID: 35390118

  • 1. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C, Abboud K.
    Am J Health Syst Pharm; 2022 Jul 22; 79(15):1224-1235. PubMed ID: 35390118
    [Abstract] [Full Text] [Related]

  • 2. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT.
    Oncotarget; 2017 Jan 10; 8(2):3724-3745. PubMed ID: 27741508
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA, Yen AE, Weigel NL.
    Pharmacol Ther; 2013 Dec 10; 140(3):223-38. PubMed ID: 23859952
    [Abstract] [Full Text] [Related]

  • 5. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K, Smith MR, Tombal B.
    Clin Genitourin Cancer; 2018 Oct 10; 16(5):332-340. PubMed ID: 30197098
    [Abstract] [Full Text] [Related]

  • 6. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
    Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP.
    Oncogene; 2014 May 29; 33(22):2815-25. PubMed ID: 23752196
    [Abstract] [Full Text] [Related]

  • 7. [Apalutamide, Erleada®].
    Sautois B, Denis C.
    Rev Med Liege; 2022 Oct 29; 77(10):609-615. PubMed ID: 36226398
    [Abstract] [Full Text] [Related]

  • 8. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
    Ming J, Wu Y, Han R, Xu X, Waldeck R, Hu S.
    Adv Ther; 2023 Mar 29; 40(3):1087-1103. PubMed ID: 36630046
    [Abstract] [Full Text] [Related]

  • 9. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology.
    Eur Urol; 2014 Feb 29; 65(2):467-79. PubMed ID: 24321502
    [Abstract] [Full Text] [Related]

  • 10. Hormonal Therapy for Prostate Cancer.
    Desai K, McManus JM, Sharifi N.
    Endocr Rev; 2021 May 25; 42(3):354-373. PubMed ID: 33480983
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M, Huang Y, Ratnam M.
    Biochem Biophys Res Commun; 2016 Jul 22; 476(2):69-74. PubMed ID: 27179779
    [Abstract] [Full Text] [Related]

  • 14. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C, Yeh S, Niu Y, Li G, Zheng J, Li L, Chang C.
    Cancer Lett; 2017 Jul 01; 397():133-143. PubMed ID: 28323036
    [Abstract] [Full Text] [Related]

  • 15. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
    Ebrahimi S, Hashemy SI, Sahebkar A, Aghaee Bakhtiari SH.
    Curr Mol Pharmacol; 2021 Oct 25; 14(4):559-569. PubMed ID: 33357209
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB.
    Eur Urol; 2015 Mar 25; 67(3):470-9. PubMed ID: 25306226
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
    Zhang Y, Liao Y, Luo M, Ye Y, Xu Z, Hou W, Liu R, Zhai Q, Lv S, Wei Q.
    Prostate; 2023 Nov 25; 83(15):1446-1457. PubMed ID: 37545197
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.